Minn Heikki, Kauhanen Saila, Seppänen Marko, Nuutila Pirjo
Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland.
J Nucl Med. 2009 Dec;50(12):1915-8. doi: 10.2967/jnumed.109.065664. Epub 2009 Nov 12.
Although 6-(18)F-fluoro-L-dopa ((18)F-FDOPA) has been available to study the striatal dopaminergic system for more than 2 decades, the full potential of the tracer was not realized before the introduction of (18)F-FDOPA PET and PET/CT to image a variety of neuroendocrine tumors (NETs) and pancreatic beta-cell hyperplasia. Together with receptor-based imaging, (18)F-FDOPA offers a formerly unforeseen means to assist in the management of NETs and infants with persistent hyperinsulinemic hyperplasia. Institutions with special expertise in surgical, oncologic, and radiologic therapeutic modalities for NETs derive the highest benefit from (18)F-FDOPA PET/CT. (18)F-FDOPA-guided therapy may add to NET control by ensuring maximal cytoreduction.
尽管6-(18)F-氟-L-多巴((18)F-FDOPA)用于研究纹状体多巴胺能系统已有20多年，但在(18)F-FDOPA正电子发射断层扫描(PET)和PET/CT用于对多种神经内分泌肿瘤(NETs)和胰腺β细胞增生进行成像之前，该示踪剂的全部潜力并未得到充分发挥。与基于受体的成像技术相结合，(18)F-FDOPA为辅助NETs管理和患有持续性高胰岛素血症性增生的婴儿提供了一种前所未有的手段。在NETs的外科、肿瘤学和放射治疗模式方面具有特殊专业知识的机构从(18)F-FDOPA PET/CT中获益最大。(18)F-FDOPA引导的治疗可能通过确保最大程度的肿瘤细胞减灭来增强对NETs的控制。
